ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1078

Improving SLEDAI-2K Documentation for Childhood-Onset Systemic Lupus Erythematosus (cSLE) in a Pediatric Rheumatology Clinic Using Quality Improvement Methodology

Ivana Stojkic1, Vinchelle Hardison1, Fatima Barbar-Smiley2, Mahmoud Kallash3, Hiren Patel3, Jonnie Lee Hughes3, James Gallop3, Ashlee Leone3, Emily Duff3, Alysha Taxter1, Stacy Ardoin1 and Vidya Sivaraman4, 1Nationwide Children's Hospital, Columbus, OH, 2Amgen, Columbus, OH, 3Nationwide Children's Hosptial, Columbus, OH, 4Nationwide Children's Hospital/ The Ohio State University, Columbus, OH

Meeting: ACR Convergence 2024

Keywords: Quality Indicators, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Measures & Measurement of Healthcare Quality Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Management of Systemic lupus erythematosus (SLE) requires accurate, timely disease activity monitoring for optimal treatment and research. The SLEDAI-2K provides objective clinical and laboratory data, but inconsistent completion rates limit its utility. This study aimed to determine baseline SLEDAI-2K documentation rates in our pediatric rheumatology clinic and implement interventions to improve them using quality improvement (QI) methodology.

Methods: A QI team reviewed all SLE clinical encounters with a physician over an eight-month period to establish baseline documentation rates. We defined a 30-day window before and after the clinic visit for SLEDAI-2K clinical and laboratory data collection. SLEDAI completion rates were tracked monthly using a p-chart. Pareto charts identified areas for improvement. Results were shared with providers during monthly QI meetings. 

Results: We identified incomplete provider-entered clinical data and delayed laboratory results as major barriers to SLEDAI-2K completion. Our first Plan-Do-Study-Act (PDSA) cycle involved implementing a “soft-stop” in the electronic health record (EHR) to alert providers of missing SLEDAI-2K documentation at time of chart closure. This alert was updated from a previous QI initiative. Additionally, we introduced an “ordered and pending” option with electronic data retrieval to allow for completion the same day. Lastly, we implemented an automated laboratory test result report outside of the EHR to obtain relevant results for SLEDAI completion, eliminating the need for providers to enter this data manually. A consolidated report caprtured all SLEDAI components for detailed analysis of missing components.  Baseline documentation rates were 70%. After implementing the PDSA cycle, rates started to improve. Completion rates were most impacted by the implementation of the EHR softstop and automation of laboratory results 

Conclusion: This project demonstrates the effectiveness of leveraging the EHR to improve SLEDAI-2K documentation. Soft-stops and electronic data retrieval addressed identified barriers and facilitated timely completion. Our QI initiative successfully improved SLEDAI-2K documentation, enhancing data quality for clinical care and research. 

Supporting image 1

The first 8-months of our complete SLEDAI documentation data was used to calculate our initial baseline mean of 70%, which is our first process stage mean. There are 4 consecutive months of complete SLEDAI Documentation percentage above our previous 70% baseline from September to December 2023. This may indicate some improvement in the SLEDAI documentation, but we need at least 4 additional months with completion above 70% to support an improvement and add a shift to a second process stage mean.

Supporting image 2

SLEDAI Completion data from September 2022-December 2023


Disclosures: I. Stojkic: None; V. Hardison: None; F. Barbar-Smiley: None; M. Kallash: None; H. Patel: None; J. Hughes: None; J. Gallop: None; A. Leone: None; E. Duff: None; A. Taxter: None; S. Ardoin: Childhood Arthritis and Rheumatology Research Alliance, 4; V. Sivaraman: None.

To cite this abstract in AMA style:

Stojkic I, Hardison V, Barbar-Smiley F, Kallash M, Patel H, Hughes J, Gallop J, Leone A, Duff E, Taxter A, Ardoin S, Sivaraman V. Improving SLEDAI-2K Documentation for Childhood-Onset Systemic Lupus Erythematosus (cSLE) in a Pediatric Rheumatology Clinic Using Quality Improvement Methodology [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/improving-sledai-2k-documentation-for-childhood-onset-systemic-lupus-erythematosus-csle-in-a-pediatric-rheumatology-clinic-using-quality-improvement-methodology/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improving-sledai-2k-documentation-for-childhood-onset-systemic-lupus-erythematosus-csle-in-a-pediatric-rheumatology-clinic-using-quality-improvement-methodology/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology